- Home
- GRND vs HRMY Comparison
GRND vs HRMY Comparison
Compare GRND & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GRND | HRMY |
|---|---|---|
| Founded | 2009 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.1B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | GRND | HRMY |
|---|---|---|
| Price | $11.25 | $26.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $22.75 | ★ $50.13 |
| AVG Volume (30 Days) | ★ 1.7M | 730.1K |
| Earning Date | 01-01-0001 | 04-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.84 |
| EPS | N/A | ★ 2.32 |
| Revenue | N/A | ★ $714,734,000.00 |
| Revenue This Year | $29.03 | $23.44 |
| Revenue Next Year | $21.87 | $16.97 |
| P/E Ratio | ★ N/A | $12.57 |
| Revenue Growth | N/A | ★ 22.80 |
| 52 Week Low | $9.79 | $25.52 |
| 52 Week High | $25.13 | $40.87 |
Technical Indicators
Market Signals| Indicator | GRND | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 51.00 | 19.96 |
| Support Level | $9.79 | $25.52 |
| Resistance Level | $14.12 | $37.98 |
| Average True Range (ATR) | 0.52 | 1.87 |
| MACD | 0.18 | -0.98 |
| Stochastic Oscillator | 84.31 | 5.75 |
Price Performance
Historical ComparisonAbout GRND Grindr Inc.
Grindr Inc is a social networking app for gay, bi, trans, and queer people. It is a social network that brings together gay and bisexual men who want to meet other men close to them in a completely discreet and anonymous way, without having to give any personal information or having to fill out a profile with confidential information in order to register.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.